Naratriptan Hexal

Naratriptan, the active ingredient in Naratriptan Hexal, is a Triptan (5‑HT1B/1D receptor agonist) presented as a tablet for oral use. It treats acute migraine attacks in adults.

GNH USA supplies Naratriptan Hexal as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Naratriptan is a selective serotonin 5‑HT1B/1D receptor agonist used in the acute treatment of migraine.

- Migraine without aura: reduces headache intensity, nausea and photophobia when taken at the start of an attack. - Migraine with aura: alleviates headache and associated visual disturbances after aura resolution. - Acute migraine attacks: provides rapid relief of pain and associated symptoms for episodic migraine sufferers.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Dizziness: transient light‑headedness. - Fatigue: feeling of tiredness. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Chest pain: possible cardiac ischemia. - Severe hypertension: marked increase in blood pressure. - Serotonin syndrome: agitation, hyperthermia, muscle rigidity when combined with other serotonergic agents.

Before prescribing Naratriptan, consider the following safety measures. - Assess cardiovascular risk: evaluate history of coronary artery disease or ischemic heart disease. - Avoid use in uncontrolled hypertension: high blood pressure may be exacerbated. - Do not combine with ergotamine derivatives: risk of excessive vasoconstriction. - Monitor for serotonin syndrome when used with SSRIs, SNRIs, or MAOIs. - Store at room temperature: keep in the original pack, protect from moisture and light.

Naratriptan may interact with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - Ergotamine derivatives: additive vasoconstriction can cause severe cardiovascular events. - Monoamine oxidase inhibitors (MAOIs): increased serotonergic activity may precipitate serotonin syndrome. - SSRIs, SNRIs, and other serotonergic agents: heightened risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - Other triptans: combined use may lead to excessive vasoconstriction. - Antihypertensive agents: potential enhancement of blood‑pressure‑lowering effects.